<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0871-3413</journal-id>
<journal-title><![CDATA[Arquivos de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Arq Med]]></abbrev-journal-title>
<issn>0871-3413</issn>
<publisher>
<publisher-name><![CDATA[ArquiMed - Edições Científicas AEFMUP ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0871-34132008000300007</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Doença de Graves]]></article-title>
<article-title xml:lang="en"><![CDATA[Graves' Disease]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Neves]]></surname>
<given-names><![CDATA[Celestino]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[Marta]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[José Luís]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[José Luís]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Hospital de São João, EPE Serviço de Endocrinologia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidade do Porto Faculdade de Medicina ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A03">
<institution><![CDATA[,Hospital de São João, EPE Serviço de Imunologia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2008</year>
</pub-date>
<volume>22</volume>
<numero>4-5</numero>
<fpage>137</fpage>
<lpage>146</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0871-34132008000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0871-34132008000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0871-34132008000300007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[A doença de Graves é a principal causa de hipertiroidismo. É uma doença auto-imune de etiologia não esclarecida, certamente multifactorial e com evidente predisposição genética. A sua frequência, a sua natureza auto-imune e as consequências potencialmente graves da doença não tratada fazem dela objecto de intensa investigação, tendo em vista a melhor compreensão dos mecanismos patogénicos e a descoberta de novas terapêuticas, mais e&#64257;cazes e idealmente dirigidas contra o próprio processo auto-imune. Os autores decidiram congregar nesta revisão o conhecimento actual mais relevante sobre o tema, de modo a optimizar a qualidade da prática clínica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Graves&#8217;disease is the major cause of hyperthyroidism. It is an autoimmune disease of a certainly multifactorial unknown etiology, with genetic predisposition evidence. Its frequency, the autoimmune nature and the potentially serious consequences of the untreated disease make it an object of intense investigation, being in mind the best understanding of the pathogenic mechanisms and the discovery of new and more efficient therapeutics, ideally directed against the autoimmune process itself. The authors decided to bring together in this revision the most relevant current knowledge on this subject, in way to optimize the quality of the clinical practice.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[doença tiroideia auto-imune]]></kwd>
<kwd lng="pt"><![CDATA[hipertiroidismo]]></kwd>
<kwd lng="pt"><![CDATA[Graves]]></kwd>
<kwd lng="en"><![CDATA[thyroid autoimmune disease]]></kwd>
<kwd lng="en"><![CDATA[hyperthyroidism]]></kwd>
<kwd lng="en"><![CDATA[Graves´ disease]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p   align="justify" ><b>Doen&ccedil;a de Graves</b> </p >     <P   align="justify" >Celestino Neves*, Marta Alves*, Jos&eacute; Lu&iacute;s Delgado&#8224;&dagger;,    Jos&eacute; Lu&iacute;s Medina* </P >     <P   align="justify" >&nbsp;</P >     <P   ><I>*Servi&ccedil;o de Endocrinologia, Hospital de S&atilde;o Jo&atilde;o, EPE,    Porto e Faculdade de Medicina da Universidade do Porto; &#8224;</I><I>Servi&ccedil;o    de Imunologia, Hospital de S&atilde;o Jo&atilde;o, EPE, Porto </I></P >     <P   align="justify" >&nbsp;</P >     <P   >A doen&ccedil;a de Graves &eacute; a principal causa de hipertiroidismo. &Eacute;    uma doen&ccedil;a auto-imune de etiologia n&atilde;o esclarecida, certamente    multifactorial e com evidente predisposi&ccedil;&atilde;o gen&eacute;tica. A    sua frequ&ecirc;ncia, a sua natureza auto-imune e as consequ&ecirc;ncias potencialmente    graves da doen&ccedil;a n&atilde;o tratada fazem dela objecto de intensa investiga&ccedil;&atilde;o,    tendo em vista a melhor compreens&atilde;o dos mecanismos patog&eacute;nicos    e a descoberta de novas terap&ecirc;uticas, mais e&#64257;cazes e idealmente    dirigidas contra o pr&oacute;prio processo auto-imune. Os autores decidiram    congregar nesta revis&atilde;o o conhecimento actual mais relevante sobre o    tema, de modo a optimizar a qualidade da pr&aacute;tica cl&iacute;nica. </P >     <P   ><B>Palavras-chave: </B>doen&ccedil;a tiroideia auto-imune; hipertiroidismo; Graves.  </P >     <P   >&nbsp; </P >     <P   ><b>Graves' Disease </b></P >     <P   >Graves&#8217;disease is the major cause of hyperthyroidism. It is an autoimmune    disease of a certainly multifactorial unknown etiology, with genetic predisposition    evidence. Its frequency, the autoimmune nature and the potentially serious consequences    of the untreated disease make it an object of intense investigation, being in    mind the best understanding of the pathogenic mechanisms and the discovery of    new and more efficient therapeutics, ideally directed against the autoimmune    process itself. The authors decided to bring together in this revision the most    relevant current knowledge on this subject, in way to optimize the quality of    the clinical practice.</P >     ]]></body>
<body><![CDATA[<P   > <b>Key-words:</b> thyroid autoimmune disease; hyperthyroidism; Graves&acute;    disease.</P >     <P   >&nbsp;</P >     <P   >&nbsp;</P >     <P   >Texto completo dispon&iacute;vel apenas em PDF.</P >     <p>Full text only available in PDF format.</p>     <P   >&nbsp; </P >     <P   >&nbsp;</P >     <p   align="justify" ><B>REFER&Ecirc;NCIAS </B></p >     <!-- ref --><P   align="" >1 -Graves RJ. Newly observed affection of the thyroid. London Medical and Surgical    Journal 1835;7:515. </P >     &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000021&pid=S0871-3413200800030000700001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><P   align="" >2 -Weetman AP. Graves&rsquo; Disease. N Engl J Med 2000;343: 1236-48. </P >     ]]></body>
<body><![CDATA[<P   align="justify" >3 -Vanderpump MPJ, Tunbridge WMG. The epidemiology of autoimmune thyroid disease.    In: Volp&eacute; R, ed. Autoimmune endocrinopathies. Vol. 15 of Contemporary    endocrinology. Totowa, N.J.: Humana Press, 1999:141-62. </P >     <P   align="" >4 -Davies TF. New thinking on the immunology of Graves&rsquo; disease. Thyroid    Today 1992;15:1-11. </P >     <P   align="" >5 -Davies TF et al. Pathogenesis of Graves&rsquo;disease. In Up-todate 2006.  </P >     <P   align="" >6 -Yeung SC. Graves disease. In eMedicine 2005. </P >     <P   align="" >7 -Vassart G, Dumon, JE. The thyrotropin receptor and the regulation of thyrocyte    function and growth. Endocrine Reviews 1992;13:596-611. </P >     <P   align="justify" >8 -Saavedra AP, Tsygankova OM, Prendergast GV, et al. Role of cAMP, PKA and Rap1A    in thyroid follicular cell survival. Oncogene 2002;21:778. </P >     <P   align="justify" >9 -Saito T, Endo T, Kawaguchi A, et al. Increased expression of the Na+/I- symporter    in cultured human thyroid cells exposed to thyrotropin and in Graves&rsquo;    thyroid tissue. J Clin Endocrinol Metab 1997;82:3331. </P >     <P   align="justify" >10-McLachlan SM, Pegg CA, Atherton MC, et al. TSH receptor antibody synthesis    by thyroid lymphocytes. Clin Endocrinol (Oxf) 1986;24:223. </P >     <P   align="justify" >11 -Tamai H, Kasagi K, Takaichi Y, et al. Development of spontaneous hypothyroidism    in patients with Graves&rsquo; disease treated with antithyroidal drugs: clinical,    immunological, and histological &#64257;ndings in 26 patients. J Clin Endocrinol    Metab 1989;69:49. </P >     <P   align="justify" >12 -Kraiem Z, Baron E, Kahana L, et al. Changes in stimulating and blocking TSH    receptor antibodiesin a patient undergoing three cycles of transition from hypo    to hyper-thyroidism and back to hypothyroidism. Clin Endocrinol 1992;36:211.  </P >     ]]></body>
<body><![CDATA[<P   align="justify" >13 -Tamai H, Ohsako N, Takeno K, et al. Changes in thyroid functionin euthyroid    subjects with a family history of Graves&rsquo; disease: a follow-up study of    69 patients. J Clin Endocrinol Metab 1980;51:1123. </P >     <P   align="justify" >14 -Bahn RS, Heufelder AE. Pathogenesis of Graves&rsquo; ophthalmopathy. N Engl    J Med 1993;329:1468-75. </P >     <P   align="justify" >15 -Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. Thyrotropin    receptor expression in Graves&rsquo; orbital adipose/connective tissues: potential    autoantigen in Graves&rsquo; ophthalmopathy. J Clin Endocrinol Metab 1998;83:    998-1002. </P >     <P   align="justify" >16 -Heufelder AE. Pathogenesis of Graves&lsquo; ophthalmopathy: recent controversies    and progress. Eur J Endocrinol 1995;132:532-41. </P >     <P   align="justify" >17 -McGregor AM, Petersen MM, Capiferri R, et al. Effects of radioiodine on thyrotrophin    bindinginhibitingimmunoglobulins in Graves&rsquo; disease. Clin Endocrinol 1979;11:437.  </P >     <P   align="justify" >18 -Aizawa Y, Yoshida K, Kaise N, et al. Long-term effects of radioiodine on    thyrotrophin receptor antibodies in Graves&rsquo; disease. Clin Endocrinol (Oxf)    1995;42:517. </P >     <P   align="justify" >19 -Bull RH, Coburn PR, Mortimer PS. Pretibial myxedema: a manifestation of lymphoedema?    Lancet 1993;341:403. </P >     <P   align="justify" >20 -Davies TF. In&#64257;ltrative dermopathy (pretibial myxedema) in thyroid    disease. In Uptodate 2006. </P >     <P   align="justify" >21 -Ajjan RA, Watson PF, Weetman AP. Cytokines and thyroid function. Adv Neuroimmunol    1996;6:359. </P >     <P   align="justify" >22 -Kahaly G, Forster G, Hansen C. Glycosaminoglycans in thyroid eye disease.    Thyroid 1998;8:429. </P >     ]]></body>
<body><![CDATA[<P   align="justify" >23 -Tomer Y, Barbesino G, Greenberg DA, et al. Mapping the major susceptibilitylocifor    familialGraves&rsquo;and Hashimoto&rsquo;s diseases: evidence for genetic heterogeneity    and gene interactions. J Clin Endocrinol Metab 1999;84:4656. </P >     <P   align="justify" >24 -Stenszky V, Kozma L, Balazs C, et al. The genetics of Graves&rsquo; disease:    HLA and disease susceptibility. J Clin Endocrinol Metab 1985;61:735. </P >     <P   align="justify" >25 -Tomer Y, Davies T. In: Wass, J, Shalet, S (eds), Oxford Textbook of Endocrinology,    Oxford University Press, Oxford, UK, 2000. </P >     <P   align="justify" >26 -Heward JM, Allahabadia A, Armitage M, et al. The development of Graves&rsquo;    disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab 1999;84:2398.  </P >     <P   align="justify" >27 -Heward JM, Allahabadia A, Daykin J, et al. Linkage disequilibrium between    the humanleukocyte antigen class II region of the major histocompatibility complex    and Graves&rsquo;disease: replication using a population case controland family-based    study. J Clin Endocrinol Metab 1998;83:3394-7. </P >     <P   align="justify" >28 -Chen QY, Huang W, She JX, et al. HLA-DRB108, DRB103/ DRB30101, and DRB30202    are susceptibility genes for Graves&rsquo; disease in North American Caucasians,    whereas DRB107 is protective. J Clin Endocrinol Metab 1999; 84:3182-6. </P >     <P   align="justify" >29 -Ban Y, Greenberg DA, Concepcion E, et al. Amino acid substitutions in the    thyroglobulin gene are associated with susceptibility to human and murine autoimmune    thyroid disease. Proc Natl Acad Sci USA 2003;100:15119. </P >     <P   align="justify" >30 -Tomer Y, Davies TF. Infection, thyroid disease and autoimmunity. Endocr Rev    1993;14:107. </P >     <P   align="justify" >31 -Radosavljevic VR, Jankovic SM, Marinkovic JM. Stressful life events in the    pathogenesis of Graves&rsquo; disease. Eur J Endocrinol 1996;134:6. </P >     <P   align="justify" >32 -Paavonen T. Hormonal regulation of immune responses. Ann Med 1994;26:255.  </P >     ]]></body>
<body><![CDATA[<P   align="justify" >33 -Da Silva JAP. Sex hormones, glucocorticoids, and autoimmunity: facts and    hypotheses. Ann Rheum Dis 1995; 54:6. </P >     <P   align="justify" >34 -Holm IA, Manson JE, Michels KB, et al. Smoking and other lifestyle factors    and the risk of Graves&rsquo; hyperthyroidism. Arch Intern Med 2005;165:1606.  </P >     <P   align="justify" >35 -Jansson R, Dahlberg PA, Winsa B, et al. The postpartum period constitutes    an important risk for the development of clinical Graves&rsquo; disease in young    women. Acta Endocrinol (Copenh) 1987;116:321. </P >     <P   align="justify" >36 -Laurberg P, Pedersen KM, Vestergaard H, et al. High incidence of multinodular    toxic goitre in the elderly population in a low iodine intake area vs. high    incidence of Graves&rsquo; disease in the young in a high iodine intake area:    comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and    Iceland. J Intern Med 1991;229:415. </P >     <P   align="justify" >37 -Bartalena L, Bogazzi F, Martino E. Amiodarone-induced thyrotoxicosis: a dif&#64257;cult    diagnostic and therapeutic challenge. Clin Endocrinol (Oxf) 2002;56:23. </P >     <P   align="justify" >38 -Burikhanov RB, Matsuzaki S. Excess iodine induces apoptosis in the thyroid    of goitrogen-pretreated rats in vivo. Thyroid 2000;10:123. </P >     <P   align="justify" >39 -Barclay ML et al. Lithium associated thyrotoxicosis: a re-porto f 14 cases,    with statistical analysis of incidence. Clin Endocrinol (Oxf) 1994;40:759-64.  </P >     <P   align="justify" >40 -Gilquin J, Viard J-P, Jubault V, Sert C, Kazatchkine MD. Delayed occurrence    of Graves&rsquo; disease after immune restoration with HAART: highly active    antiretroviral therapy. Lancet 1998;352:1907-8. </P >     <P   align="justify" >41 -Kendall-Taylor P. Thyrotoxicosis. In: Grossman A, ed. Clinical endocrinology.    Oxford, England: Blackwell Science, 1998:328-58. </P >     <P   align="justify" >42 -Nordyke RA, Gilbert FI Jr, Harada ASM. Graves&rsquo; disease: in&#64258;uence    of age on clinical &#64257;ndings. Arch Intern Med 1988;148:626-31. </P >     ]]></body>
<body><![CDATA[<P   align="justify" >43 -Ross DS. Overview of the clinical manifestations of hyperthyroidism in adults.    In Uptodate 2006. </P >     <P   align="justify" >44 -Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the    Management of Patients With Atrial Fibrillation A Report of the American College    of Cardiology/ American Heart Association Task Force on Practice Guidelines    and the European Society of Cardiology Committee for Practice Guidelines (Writing    Committee to Revise the 2001 Guidelines for the Management of Patients With    Atrial Fibrillation). J Am Coll Cardiol 2006;48:e149. </P >     <P   align="justify" >45 -Iglesias P, Acosta M, Sanchez R, et al. Ambulatory blood pressure monitoringin    patients with hyperthyroidism before and after control of thyroid function.    Clin Endocrinol (Oxf) 2005;63:66. </P >     <P   align="justify" >46 -Kirkeby K, Hangaard G, Lingjaerde P. The pigmentation of thyrotoxic patients.    Acta Med Scand 1963;174:257. </P >     <P   align="justify" >47 -O&rsquo;Brien T, Katz K, Hodge D, et al. The effect of the treatment of hypothyroidism    and hyperthyroidism on plasmalipids and apoproteins AI, AII and E. Clin Endocrinol    1997;46:17. </P >     <P   >48 -Villadolid MC, Yokoyama N, Izumi M, et al. Untreated Graves&#8217; disease    patients without clinical ophthalmopathy demonstrate a high frequency of extraocular    muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 1995;80:2830-3.  </P >     <P   >49 -Perros P, Crombie AL, Matthews JNS, Kendall-Taylor P. Age and gender influence    the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending    a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 1993;38:367-372. </P >     <P   >50 -Fatourechi V, Pajouhi M, Fransway AF. Dermopathy of Graves&#8217; disease    (pretibial myxedema): review of 150 cases. Medicine (Baltimore) 1994;73:1-7.  </P >     <P   >51 -Carnell NE, Valent WA. Thyroid nodules in Graves&#8217; disease: classification,    characterization, and response to treatment. Thyroid 1998;8:647-52. (Erratum,    Thyroid 1998;8:1079.) </P >     <P   >52 -Alves M, Neves C, Delgado JL, Medina JL. Disfun&ccedil;&atilde;o tiroideia    na gravidez. Rev Port End Diab Metab2007;2:47- 56. </P >     ]]></body>
<body><![CDATA[<P   >53 -Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with    hyperthyroidism and hypothyroidism. JAMA 1995;273:808. </P >     <P   >54 -Torring O, Tallstedt L, Wallin G, et al. Graves&#8217; hyperthyroidism: treatment    with antithyroid drugs, surgery, or radioiodine - a prospective, randomized    study. J Clin Endocrinol Metab 1996;81:2986. </P >     <P   >55 -Ross D. Beta blockers in the treatment of hyperthyroidism. In Uptodate 2006.  </P >     <P   >56 -Ross DS. Treatment of Graves&#8217; hyperthyroidism. In Uptodate 2006. </P >     <P   >57 -Lavin N. Manual of Endocrinology and Metabolism. Lippincott Williams and    Wilkins. 3&ordf; edi&ccedil;&atilde;o, 2002. </P >     <P   >58 -Cooper DS. Antithyroid drugs. N Engl J Med 2005;352;9: 905-17. </P >     <P   >59 -Ross D. Surgery in the treatment of hyperthyroidism. In Uptodate 2006.</P >     <P   >60 -Davies TF. Tretment of Graves&#8217; ophthalmopathy. In Uptodate 2006. </P >     <P   >61 -Eastell R, Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate    in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000;11:331.  </P >     <P   >62 -Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of    intravenous versus oral steroid monotherapy in Graves&#8217; orbitopathy. J    Clin Endocrinol Metab 2005;90:5234.</P >     ]]></body>
<body><![CDATA[<P   >63 -Nygaard B, Specht L. Transitory blindness after retrobulbar irradiation of    Graves&#8217; ophthalmopathy. Lancet 1998; 351:725. </P >     <P   >64 -Lyons CJ, Rootman J. Orbital decompression for disfiguring exophthalmos in    thyroid orbitopathy. Ophthalmology 1994;101:223.</P >     <P   >65 -Braley-Mullen H, Yu S. Early requirement for B cells for development of spontaneous    autoimmune thyroiditis in NOD.H-2h4 mice. J Immunol 2000,,165:7262-9. </P >     <P   >66 -Segundo C, Rodriguez C, Aguilar M, Garcia-Poley A, Gavilan Bellas CI, Brieva    JA. Differences in thyroid-infiltrating B lymphocytes in patients with Graves&#8217;    disease: relationship to autoanti-body detection. Thyroid 2004;14:337-44. </P >     <P   >67 -Armengol MP, Juan M, Lucas-Martin A, Fernandez-Figueras Jaraquemada DMT,    Gallart T, Pujol-Borrell R. Thyroid autoimmune disease: demonstration of thyroid    antigen-specific B cells and recombination-activating gene expression in chemokine-containing    active intrathyroidal germinal centers. Am J Pathol 2001;159:861-73.</P >     <P   >68 -Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation    in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8. </P >     <P   >69 -Pichurin P, Aliesky H, Chen CR, Nagayama Y, Rapoport B, McLachlan SM. Thyrotrophin    receptor-specific memory T cell responses require normal B cells in a murine    model of Graves&#8217; disease. Clin Exp Immunol 2003;134:396-402. </P >     <P   >70 -Boye J, Elter T &amp; Engert A. An overview of the current clinical use of    the anti-CD20 monoclonal antibody rituximab. Annals of Oncology 2003;14:520-35.  </P >     <P   >71 -Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA,    Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human    monoclonal antibody to CD20. Blood 1994;83:435-45. </P >     <P   >72 -Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in    the treatment of autoimmune diseases. Immunobiology 2002;206:519-27. </P >     ]]></body>
<body><![CDATA[<P   >73 -Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential    as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74. </P >     <P   >74 -Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action    and resistance. Oncogene 2003; 22:7359-68. </P >     <P   >75 -Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes    drive human autoimmune disease? Immunology 1999;97:188-96.</P >     <P   >76 -El Fassi D, Nielsen CH, Hasselbalch HC, Hegedus L. Successful B lymphocyte    depletion with Rituximab in a patient with recurrent Graves&#8217; disease and    severe ophthalmopathy. Thyroid 2005;15:S28. </P >     <P   >77 -Smith TJ. Insights into the role of fibroblasts in human autoimmune diseases.    Clin Exp Immunol. 2005;141: 388-97. </P >     <P   >78 -Pritchard J, Tsui S, Horst N, Cruikshank WW, Smith TJ. Synovial fibroblasts    from patients with rheumatoid arthritis, like fibroblasts from Graves&#8217;    disease, express high levels of IL-16 when treated with Igs against insulin-like    growth factor-1 receptor. J Immunol 2004;173:3564-9. </P >     <P   >79 -Nielse CH, El Fassi D, Hasselbach HC, Bendtzen K, Heged&uuml;s L. B-cell    depletion with rituximab in the treatment of autoimmune diseases. Graves&#8217;    ophthalmopathy the latest addition to an expanding family. Expert Opin Biol    Ther 2007;7:1061-78. </P >     <P   >80 -Fassi ED, Nielsen CH, Hasselbalch HC, Heged&uuml;s L. The rationale for B    lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy    as a novel treatment option 2006. Eur J Endocrinol 2006;154:623-32.</P >     <P   >&nbsp;</P >     <P   ><b>Correspond&ecirc;ncia:</b></P >     ]]></body>
<body><![CDATA[<P   > Dr. Celestino Neves</P >     <P   > Servi&ccedil;o de Endocrinologia</P >     <P   > Hospital de S&atilde;o Jo&atilde;o</P >     <P   > Alameda Prof. Hern&acirc;ni Monteiro </P >     <P   >4200-319 Porto </P >     <P   >e-mail: <a href="mailto:celestino.neves@sapo.pt">celestino.neves@sapo.pt</a></P >      ]]></body>
<back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graves]]></surname>
<given-names><![CDATA[RJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Newly observed affection of the thyroid.]]></article-title>
<source><![CDATA[London Medical and Surgical Journal]]></source>
<year>1835</year>
<volume>7</volume>
<page-range>515</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
